Semax

21 indexed publications · 5 human studies · research from 1997 to 2026

Research goals studied

  • Cardiovascular
  • Delivery & pharmacokinetics
  • Gene & DNA regulation
  • Immune function
  • Longevity & aging
  • Mood, stress & sleep
  • Neuro & cognition
  • Skin & tissue repair

Studies referencing Semax

  • Therapeutic Peptides in Gerontology: Mechanisms and Applications for Healthy Aging

    2026 · Preclinical

    Reviews nine peptides, including Epitalon and Semax, and stresses that long-term safety and systematic clinical validation remain limited.

  • The Potential of the Peptide Drug Semax and Its Derivative for Therapeutic and Corrective Strategies in Alzheimer's Disease

    2025 · Preclinical

    Reported behavioral and molecular effects of Semax-related compounds in preclinical models.

  • The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain

    2021 · Preclinical

    Rat ischemia study examining Semax effects on pro-inflammatory transcript expression.

  • Semax as a Synthetic ACTH(4-10) Analogue in Ischemic Brain Injury

    2021 · Preclinical

    Summarizes neuroprotective pathways and preclinical ischemia findings.

  • Semax Alters the Brain Proteomic Profile after Ischemic Injury

    2021 · Preclinical

    Identified protein-expression changes after Semax in an ischemia model.

  • RNA-Sequencing Analysis of Semax Effects after Transient Middle Cerebral Artery Occlusion

    2020 · Preclinical

    Reported gene-expression changes in rat brain after transient ischemia and Semax treatment.

  • Effects of Semax and Selank on Resting-State Functional Connectivity

    2020 · Human evidence

    Examined acute changes in resting-state network connectivity after intranasal peptides in healthy participants.

  • Immunocorrective Effects of Semax

    2019 · Preclinical

    Reported immunomodulatory effects in an experimental model.

  • Semax Effects on Resting-State Brain Networks in Healthy Volunteers

    2018 · Human evidence

    Human neuroimaging study examining acute Semax-related network changes.

  • Semax in Rehabilitation after Ischemic Stroke and Its Relationship to BDNF

    2018 · Human evidence

    Evaluated neurological recovery and BDNF-related measures during post-stroke rehabilitation.

  • Peptides Semax and Selank Affect the Behavior of Rats with 6-OHDA-Induced Dopaminergic System Damage

    2017 · Preclinical

    Compared behavioral effects of Semax and Selank after 6-OHDA dopaminergic injury.

  • Semax, an Analog of ACTH(4-7), Regulates Expression of Immune Response Genes During Ischemic Brain Injury in Rats

    2017 · Preclinical

    Examined Semax-associated gene-expression changes after experimental brain ischemia.

  • The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia

    2014 · Preclinical

    Reported early gene-expression changes after focal cerebral ischemia.

  • Semax and Pro-Gly-Pro Stimulate Cell Proliferation after Ischemic Injury

    2011 · Preclinical

    Reported increased proliferative-cell markers after ischemic injury.

  • Nootropic and Analgesic Effects of Semax Following Different Routes of Administration

    2010 · Preclinical

    Compared intraperitoneal and intranasal Semax in rats using learning and pain-sensitivity tests.

  • Specific Binding of Semax and Its Effect on BDNF Expression in Rat Brain

    2006 · Preclinical

    Investigated Semax binding and associated BDNF-expression changes.

  • Semax Regulates the Expression and Activation of the Hippocampal BDNF/trkB System

    2006 · Preclinical

    Assessed hippocampal BDNF/trkB responses after Semax administration.

  • Neuroprotective Effects of Semax in MPTP-Induced Disturbances of the Dopaminergic System

    2002 · Preclinical

    Evaluated behavioral and neuroprotective effects of Semax in an MPTP rat model.

  • Semax and Selank Inhibit Enkephalin-Degrading Enzymes in Human Serum

    2001 · Preclinical

    Tested effects of Semax and Selank on enzymes involved in enkephalin degradation.

  • Semax in Acute Ischemic Stroke: Clinical and Mechanistic Observations

    1999 · Human evidence

    Early clinical report; treatment allocation and masking require full-text appraisal.

  • Semax in the Treatment of Patients at Different Stages of Ischemic Stroke

    1997 · Human evidence

    Early clinical report of Semax use at different stages of ischemic stroke; full protocol appraisal is required.

Working with Semax?

Convert a vial to draw volume on the peptide calculator, or track protocols and vials in the free app.

Start tracking free